Drug intelligence / Profile preview

ST-502

Development stage: Discontinued
Lead developer: Biogen
Modality: Gene Therapies
Administration: Parenteral

Overview

ST-502 is a gene therapy developed by Sangamo Therapeutics using zinc finger DNA binding protein technology. Its mechanism of action is to inhibit alpha-synuclein and gene transcription, aiming to address the underlying molecular pathology of Parkinson's disease. The therapy is intended to modulate genetic activity in neurons through selective inhibition, and was in preclinical development for Parkinson's disease. Biogen was previously a development partner, but their licensing agreement was terminated as of June 2023[1][3].

Other names: ST502ST-502ST 502

Targets

SNCA (Alpha-synuclein)

Beyond the preview

Go deeper on ST-502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST-502.

Explore the full profile